Related Experiment Videos
[Interferon treatment of type C fulminant hepatitis]
M Yoshiba1, K Inoue, K Sekiyama
1Division of Gastroenterology, Showa University Fujigaoka Hospital.
Insights
Fulminant hepatitis type C (FH) is common in Asia, unlike Western countries. Enhanced immune responses may drive liver damage, with interferon and immunosuppressants offering potential treatment.
Area of Science:
- Hepatology
- Virology
- Immunology
Context:
- Fulminant hepatitis type C (FH) presents a significant health burden in Asian populations, contrasting with Western epidemiology.
- Coinfection with hepatitis A and B viruses is observed in some FH cases.
- The precise mechanisms underlying FH pathogenesis remain incompletely understood.
Purpose:
- To explore the characteristics and potential pathogenesis of type C fulminant hepatitis (FH).
- To investigate the role of host immune responses in hepatocyte destruction in type C FH.
- To review current treatment strategies and prognostic factors for type C FH.
Summary:
- Type C FH, prevalent in Asia, involves gradual liver necrosis potentially due to persistent hepatitis C virus infection.
- Enhanced host immune responses are implicated in driving hepatocyte destruction.
- Treatment involves interferon combined with immunosuppressive agents, with early intervention improving prognosis.
Impact:
- Highlights the distinct epidemiological profile of type C FH in Asia.
- Suggests a crucial role for the host immune system in FH progression.
- Emphasizes the importance of timely treatment for better patient outcomes.
Abstract:
On the contrary to Western countries, there are a substantial number of patients with type C fulminant hepatitis (FH) including coinfection on type A and type B hepatitis in Asian countries. The pathogenesis of FH is not fully understood, however, recent clinical observations suggest that enhanced host immune responses contribute to hepatocyte destruction in type C FH. In contrast to type B FH, type C FH is characterized by gradual and continuous liver necrosis probably duo to persistent infection of hepatitis C virus. Administration of interferon with immunosuppressive agents is the treatment of choice. Prognosis may be improved if the treatment is started in the early stage of the disease.